ACRS earnings analysis
What we found in ACRS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Aclaris Therapeutics reported strong Q1 2026 earnings with revenues of $1.996 million, exceeding estimates significantly. Although the company continued to incur losses, reporting a net loss of $19.8 million, it maintained a solid cash position of $190.8 million, indicating stability in funding future operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Exceeds Estimates
- Actual revenue for Q1 2026 was $1.996 million, a 37.2% increase from $1.455 million in Q1 2025, surpassing estimates by 49.9%.
- Improved EPS Performance
- Reported EPS was -$0.15, compared to -$0.12 in Q1 2025, a smaller loss indicating improved relative performance.
- Strong Cash Position
- As of March 31, 2026, Aclaris had cash, cash equivalents, and marketable securities totaling $190.8 million, up from $131.4 million at year-end 2025.
- Increased Licensing Revenue
- Licensing revenue increased to $1.459 million in Q1 2026 from $1.010 million in Q1 2025, due to higher royalties under license agreements.
- Positive Developments in Clinical Trials
- Management highlighted encouraging preliminary results from ongoing clinical trials, particularly for bosakitug and ATI-052.
- Capital Raising Success
- In March 2026, Aclaris raised $59.8 million from the sale of common stock, enhancing its liquidity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Net Losses
- Net loss reported for Q1 2026 was $19.8 million, significantly higher than the $15.1 million loss in Q1 2025.
- Operational Cash Flow Concerns
- Cash used in operating activities increased to $18.149 million in Q1 2026 from $13.057 million in Q1 2025.
- Dependence on Future Clinical Success
- Continued reliance on successful outcomes from clinical trials and regulatory approvals poses a substantial risk to cash flow.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.15
What they said about what is next.
Aclaris expects to continue funding operations through 2028 based on current liquidity.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Aclaris is a clinical-stage immuno-inflammatory biopharma emphasizing biologics (TSLP and bispecific TSLP/IL-4Rα) and small-molecule ITK programs driven by its KINect discovery platform. The 10-K highlights multiple…
- 10-Q · August 7, 2025
- Aclaris reported quarterly revenue of $1.777M for Q2 2025, down from $2.766M in Q2 2024, while GAAP net loss widened to $15.429M (−$0.13/share) despite EPS improving vs prior-year quarter due to a larger share base.…
- 10-Q · November 6, 2024
- Aclaris reported Q3 revenue of $4,346,000, down from $9,282,000 in Q3 2023, driven by a sharp decline in licensing revenue. Gross margin remained high at ~85% (revenue $4,346,000 less cost of revenue $654,000) and…
- 10-Q · August 7, 2023
- Aclaris reported Q2 2023 revenue of $1,869,000 (up from $1,528,000 in Q2 2022) and a GAAP net loss per share of $(0.42). Licensing revenue drove the top-line increase while R&D spend rose materially, pushing loss from…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACRS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever